TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy
Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor.
RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT
BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.
$30M for Cancer-Focused TAE Life Sciences
HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG
Tiny Yet Mighty: Nanotechnology in Radiation Therapy
Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.
New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal
BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.
TAE Life Sciences Inks $40M Series A Funding
TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.
TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.
TAE Raises $40M To Develop New Targeted Radiotherapy
Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.